Head-To-Head Survey: Apollo Endosurgery (APEN) versus Tactile Systems Technology (TCMD)
Apollo Endosurgery (NASDAQ: APEN) and Tactile Systems Technology (NASDAQ:TCMD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.
This is a summary of recent ratings and recommmendations for Apollo Endosurgery and Tactile Systems Technology, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tactile Systems Technology||0||2||3||0||2.60|
Apollo Endosurgery currently has a consensus price target of $11.00, indicating a potential upside of 158.82%. Tactile Systems Technology has a consensus price target of $35.50, indicating a potential upside of 29.94%. Given Apollo Endosurgery’s stronger consensus rating and higher possible upside, analysts plainly believe Apollo Endosurgery is more favorable than Tactile Systems Technology.
Earnings & Valuation
This table compares Apollo Endosurgery and Tactile Systems Technology’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Apollo Endosurgery||$64.87 million||1.13||-$41.16 million||($36.74)||-0.12|
|Tactile Systems Technology||$84.54 million||5.70||$2.87 million||$0.25||109.28|
Tactile Systems Technology has higher revenue and earnings than Apollo Endosurgery. Apollo Endosurgery is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Apollo Endosurgery has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500.
Insider and Institutional Ownership
8.9% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 45.7% of Tactile Systems Technology shares are owned by institutional investors. 74.2% of Apollo Endosurgery shares are owned by insiders. Comparatively, 49.9% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Apollo Endosurgery and Tactile Systems Technology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tactile Systems Technology||4.97%||3.05%||2.54%|
Tactile Systems Technology beats Apollo Endosurgery on 8 of the 12 factors compared between the two stocks.
About Apollo Endosurgery
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
About Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
Receive News & Ratings for Apollo Endosurgery Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.